The effect of IL-6 inhibitor (Tocilizumab) on the prognosis of covid-19 patients with acute respiratory failure hospitalized in Imam Reza Hospital in Tabriz

The effect of IL-6 inhibitor (Tocilizumab) on the prognosis of covid-19 patients with acute respiratory failure

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20200406046968N1

Enrollment

Registered

2020-04-14

Start date

2020-04-21

Completion date

Unknown

Last updated

2020-05-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19 disease. COVID-19 disease

Interventions

Intervention 1: Intervention group: Patients with COVID-19, in addition to the usual treatment, receive Tocilizumab IL-6 at a dose of 400 mg diluted in 155 cc of normal saline for one hour as a single

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: Age range 18-70 P/F7

Exclusion criteria

Exclusion criteria: Acute or chronic renal failure Increased liver enzymes 3 times normal with gastrointestinal symptoms or abdominal pain and nausea and jaundice or increased liver enzymes 5 times normal - liver cirrhosis Pregnancy latent TB Active gastric ulcer Dissatisfaction with entering the study

Design outcomes

Primary

Measure	Time frame
Percentage of effect of Tocilizumab on COVID-19 patients. Timepoint: Patients receive the drug in a single dose over an hour, and resorption monitoring will be performed to improve oxygenation status and subsequent complications in vital organs of the heart, kidneys, CNS, hemodynamic disturbances, duration of mechanical ventilation, and eventual mortality. Method of measurement: Clinical and laboratory testing.	—

Measure

Time frame

Percentage of effect of Tocilizumab on COVID-19 patients. Timepoint: Patients receive the drug in a single dose over an hour, and resorption monitoring will be performed to improve oxygenation status and subsequent complications in vital organs of the heart, kidneys, CNS, hemodynamic disturbances, duration of mechanical ventilation, and eventual mortality. Method of measurement: Clinical and laboratory testing.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMikaili, haleh

Tabriz University of Medical Sciences

halehmikaeili@gmail.com+98 41 3329 6024

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026